PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26813676-5	2016	The dependence of ATL cells to Pim1 activity was demonstrated using 2 Pim1 small inhibitors, SMI-4a and AZD1208.	SMI-4a	93-99	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	31-35
28170315-5	2017	Inhibition of Pim-1 activity using the selective pharmaceutic inhibitor Smi-4a significantly reduced the level of lactate production and glucose uptake after cytoplasmic irradiation.	SMI-4a	72-78	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	14-19
33185705-10	2021	The PIM1 specific inhibitor SMI-4a administration relieved the severity of endotoxin-induced ALI.	SMI-4a	28-34	proviral integration site 1	Mus musculus	4-8
26088877-7	2016	Data indicated Pim kinase inhibitors in combination with ABT-737 or ABT-199 resulted mostly in additive cytotoxicity with a few synergistic responses; however, the extent of synergism was less robust than that observed previously in prostate cancer cell lines treated with SMI-4a and ABT-737.	SMI-4a	273-279	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	15-18
19965690-2	2010	We demonstrate that SMI-4a, a novel benzylidene-thiazolidine-2, 4-dione small molecule inhibitor of the Pim kinases, kills a wide range of both myeloid and lymphoid cell lines with precursor T-cell lymphoblastic leukemia/lymphoma (pre-T-LBL/T-ALL) being highly sensitive.	SMI-4a	20-26	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	104-107
19965690-4	2010	In addition, treatment of these cells with SMI-4a was found to induce phosphorylation of extracellular signal-related kinase1/2 (ERK1/2), and the combination of SMI-4a and a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor was highly synergistic in killing pre-T-LBL cells.	SMI-4a	43-49	mitogen-activated protein kinase 3	Homo sapiens	89-127
19965690-4	2010	In addition, treatment of these cells with SMI-4a was found to induce phosphorylation of extracellular signal-related kinase1/2 (ERK1/2), and the combination of SMI-4a and a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor was highly synergistic in killing pre-T-LBL cells.	SMI-4a	43-49	mitogen-activated protein kinase 3	Homo sapiens	129-135
19965690-4	2010	In addition, treatment of these cells with SMI-4a was found to induce phosphorylation of extracellular signal-related kinase1/2 (ERK1/2), and the combination of SMI-4a and a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor was highly synergistic in killing pre-T-LBL cells.	SMI-4a	43-49	mitogen-activated protein kinase kinase 1	Homo sapiens	174-217
19965690-4	2010	In addition, treatment of these cells with SMI-4a was found to induce phosphorylation of extracellular signal-related kinase1/2 (ERK1/2), and the combination of SMI-4a and a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor was highly synergistic in killing pre-T-LBL cells.	SMI-4a	43-49	mitogen-activated protein kinase kinase 1	Homo sapiens	219-225
32619930-5	2020	Furthermore, PIM1 inhibition by the PIM1-specific inhibitor SMI-4a showed protective effects against BLM-induced mortality.	SMI-4a	60-66	proviral integration site 1	Mus musculus	13-17
32619930-5	2020	Furthermore, PIM1 inhibition by the PIM1-specific inhibitor SMI-4a showed protective effects against BLM-induced mortality.	SMI-4a	60-66	proviral integration site 1	Mus musculus	36-40
31358902-7	2019	Further, treatment with a combination of the PIM2 inhibitor SMI-4a and the AMPKalpha1 activator AICAR could effectively inhibit tumor growth.	SMI-4a	60-66	proviral integration site 2	Mus musculus	45-49
31203114-0	2019	PIM1 inhibitor SMI-4a attenuated lipopolysaccharide-induced acute lung injury through suppressing macrophage inflammatory responses via modulating p65 phosphorylation.	SMI-4a	15-21	proviral integration site 1	Mus musculus	0-4
31203114-0	2019	PIM1 inhibitor SMI-4a attenuated lipopolysaccharide-induced acute lung injury through suppressing macrophage inflammatory responses via modulating p65 phosphorylation.	SMI-4a	15-21	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	147-150
31203114-4	2019	Histology, wet/dry (W/D) ratio, inflammatory cells in the bronchoalveolar lavage fluid (BALF) and survival rate analyses were performed when mice received the PIM1 inhibitor SMI-4a intratracheally 3 h before LPS administration.	SMI-4a	174-180	proviral integration site 1	Mus musculus	159-163
31203114-9	2019	The PIM1 inhibitor SMI-4a suppressed the production of cytokines in LPS-treated RAW264.7 cell supernatants and BALF.	SMI-4a	19-25	proviral integration site 1	Mus musculus	4-8
29483938-7	2018	Conclusions: Our results suggested that SMI-4a could enhance autophagy-inducing apoptosis by inhibiting AKT/mTOR signaling pathway in melanoma cells, and G-Rh2 could enhance the effects of SMI-4a against melanoma cancer via amplifying autophagy induction.	SMI-4a	40-46	AKT serine/threonine kinase 1	Homo sapiens	104-107
31114247-0	2019	Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway.	SMI-4a	16-22	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	0-5
31114247-0	2019	Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway.	SMI-4a	16-22	AKT serine/threonine kinase 1	Homo sapiens	86-89
31114247-0	2019	Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway.	SMI-4a	16-22	mechanistic target of rapamycin kinase	Homo sapiens	90-94
30658101-0	2019	PIM inhibitor SMI-4a induces cell apoptosis in B-cell acute lymphocytic leukemia cells via the HO-1-mediated JAK2/STAT3 pathway.	SMI-4a	14-20	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	0-3
30658101-0	2019	PIM inhibitor SMI-4a induces cell apoptosis in B-cell acute lymphocytic leukemia cells via the HO-1-mediated JAK2/STAT3 pathway.	SMI-4a	14-20	Janus kinase 2	Homo sapiens	109-113
30658101-0	2019	PIM inhibitor SMI-4a induces cell apoptosis in B-cell acute lymphocytic leukemia cells via the HO-1-mediated JAK2/STAT3 pathway.	SMI-4a	14-20	signal transducer and activator of transcription 3	Homo sapiens	114-119
30658101-10	2019	Treatment with SMI-4a induced apoptosis by downregulating Bcl-2, upregulating Bax and other antiapoptotic proteins, and decreasing protein levels of p-JAK2 and p-STAT3.	SMI-4a	15-21	BCL2 apoptosis regulator	Homo sapiens	58-63
30658101-10	2019	Treatment with SMI-4a induced apoptosis by downregulating Bcl-2, upregulating Bax and other antiapoptotic proteins, and decreasing protein levels of p-JAK2 and p-STAT3.	SMI-4a	15-21	BCL2 associated X, apoptosis regulator	Homo sapiens	78-81
30658101-10	2019	Treatment with SMI-4a induced apoptosis by downregulating Bcl-2, upregulating Bax and other antiapoptotic proteins, and decreasing protein levels of p-JAK2 and p-STAT3.	SMI-4a	15-21	Janus kinase 2	Homo sapiens	151-155
30658101-10	2019	Treatment with SMI-4a induced apoptosis by downregulating Bcl-2, upregulating Bax and other antiapoptotic proteins, and decreasing protein levels of p-JAK2 and p-STAT3.	SMI-4a	15-21	signal transducer and activator of transcription 3	Homo sapiens	162-167
29985480-7	2018	Interestingly, PIM2 kinase inhibitor SMI-4a could abrogate the effects of phosphorylated HK2 Thr473 on paclitaxel resistance in vitro and in vivo.	SMI-4a	37-43	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	15-19
29985480-7	2018	Interestingly, PIM2 kinase inhibitor SMI-4a could abrogate the effects of phosphorylated HK2 Thr473 on paclitaxel resistance in vitro and in vivo.	SMI-4a	37-43	hexokinase 2	Homo sapiens	89-92
29483938-7	2018	Conclusions: Our results suggested that SMI-4a could enhance autophagy-inducing apoptosis by inhibiting AKT/mTOR signaling pathway in melanoma cells, and G-Rh2 could enhance the effects of SMI-4a against melanoma cancer via amplifying autophagy induction.	SMI-4a	40-46	mechanistic target of rapamycin kinase	Homo sapiens	108-112